Antares Pharma, Inc. Announces Launch of Tjet Needle-Free Injector System by Marketing Partner Teva Pharmaceutical Industries Limited
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has launched its new Tjet™ needle-free injector system for the administration of human growth hormone (hGH). The Tjet™ device will be available exclusively in combination with the Teva hGH product Tev-Tropin® [somatropin (rDNA) for injection].